Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adjunctive 308-nm Excimer Light With Oral Azithromycin for Inflammatory Acne
Sponsor: Mahmoud Rageh
Summary
This randomized, evaluator-blinded, split-face study evaluated whether adjunctive lesion-directed 308-nm excimer light improves inflammatory acne outcomes during oral azithromycin therapy. All participants received oral azithromycin 500 mg three times weekly for 8 weeks. One randomly allocated hemiface additionally received 308-nm excimer light twice weekly for 8 weeks, while the contralateral hemiface served as the azithromycin-only control. Papule and pustule counts and hemiface Investigator's Global Assessment were assessed through Week 8. Investigator's Global Assessment was reassessed at Week 16 after an 8-week treatment-free follow-up. We hypothesized that the excimer-treated hemiface would demonstrate greater reduction in total inflammatory-lesion count by Week 8.
Official title: Efficacy and Tolerability of Adjunctive 308-nm Excimer Light During Oral Azithromycin Therapy for Inflammatory Acne Vulgaris: A Randomized, Evaluator-Blinded, Split-Face Controlled Trial
Key Details
Gender
All
Age Range
15 Years - 35 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-10-12
Completion Date
2026-05-10
Last Updated
2026-08-21
Healthy Volunteers
No
Conditions
Interventions
308-nm Excimer Light
Monochromatic 308-nm excimer light was delivered using the KN-5000C device. Irradiation was lesion-directed and administered twice weekly for 8 weeks, with at least 48 hours between sessions, for a planned total of 16 sessions. Treatment began at 0.15 J/cm² and was increased according to erythema response and device dose settings, up to a maximum of 0.65 J/cm².
Azithromycin
Description: Oral azithromycin 500 mg was administered after meals three times weekly for 8 weeks, corresponding to 24 scheduled doses.
Locations (1)
Al-Azhar University Hospital
Damietta, Egypt